RxDoctor Payments Data

Alexandra Scherk, OD

Optometrist · Great Neck, NYNPI 1831683648

Payments from drug & device makers

$2,973in general payments, 2019–2025

Across 111 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$586
  • Novartis$427
  • AbbVie$422
  • Johnson & Johnson Vision Care, Inc.$347
  • Sun Pharmaceutical Industries Inc.$192
  • Alcon$180
  • plus $818 from 15 others

What the payments were for

  • Food & beverage$2,95499%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,973 in reported general payments places this provider in the 85th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$122,569
Medicare patients
616
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$96,432
XiidraLifitegrast14$25,835
LumiganBimatoprost35$16,761
TyrvayaVarenicline Tartrate18$11,521
CombiganBrimonidine Tartrate/Timolol44$9,251
Alphagan PBrimonidine Tartrate21$7,651
VyzultaLatanoprostene Bunod27$6,774
ZioptanTafluprost/Pf11$2,868
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$2,034
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha81$887
Latanoprost117$776
Brimonidine Tartrate13$438
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$372
Azelastine Hcl11$290
Ofloxacin26$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$422$130,095172 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$117$32,61041 claims
Oyster Point Pharma, Inc.Tyrvaya$586$11,52118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,743 optometrist providers in New York.

Other optometrist in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →